Compare Stocks → Don’t Miss Out on the AI Gold Rush That’s Just Getting Started (From Banyan Hill Publishing) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ITRMNASDAQ:KZRNASDAQ:MLNDNASDAQ:SVRA Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeITRMIterum Therapeutics$1.58$1.51$0.62▼$2.50$25.96M2.36513,357 shs36,278 shsKZRKezar Life Sciences$0.83+0.5%$0.89$0.67▼$3.13$60.13M0.47697,721 shs517,867 shsMLNDMillendo Therapeutics$3.24+4.5%$4.00$0.92▼$16.95$61.70M0.481.52 million shs391,140 shsSVRASavara$4.69-0.2%$4.96$1.76▼$5.70$647.92M0.77844,615 shs479,493 shs10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceITRMIterum Therapeutics+8.39%+0.65%-3.13%-22.11%+44.86%KZRKezar Life Sciences+4.05%+1.54%-15.65%+0.24%-66.99%MLNDMillendo Therapeutics+4.52%-2.99%-10.99%-19.80%+41.48%SVRASavara-2.29%-6.75%-2.08%-6.93%+161.11%Don’t Miss Out on the AI Gold Rush That’s Just Getting Started (Ad)“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.See how you can invest alongside himMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationITRMIterum Therapeutics0.8673 of 5 stars3.52.00.00.00.60.00.6KZRKezar Life Sciences3.9029 of 5 stars3.22.00.04.61.91.71.3MLNDMillendo TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ASVRASavara1.4433 of 5 stars3.51.00.00.02.01.70.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceITRMIterum Therapeutics3.00Buy$6.00279.75% UpsideKZRKezar Life Sciences2.33Hold$11.001,231.72% UpsideMLNDMillendo TherapeuticsN/AN/AN/AN/ASVRASavara3.00Buy$8.2074.84% UpsideCurrent Analyst RatingsLatest KZR, SVRA, MLND, and ITRM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/18/2024SVRASavaraJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$8.004/1/2024ITRMIterum TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.003/15/2024KZRKezar Life SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.003/6/2024ITRMIterum TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.003/4/2024SVRASavaraPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$7.00 ➝ $16.002/15/2024SVRASavaraJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$8.002/7/2024ITRMIterum TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$6.00(Data available from 4/23/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookITRMIterum TherapeuticsN/AN/AN/AN/A($0.48) per shareN/AKZRKezar Life Sciences$7M8.59N/AN/A$2.58 per share0.32MLNDMillendo TherapeuticsN/AN/AN/AN/A$1.78 per shareN/ASVRASavaraN/AN/AN/AN/A$1.04 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateITRMIterum Therapeutics-$38.37M-$2.97N/AN/AN/AN/A-664.00%-87.64%5/10/2024 (Estimated)KZRKezar Life Sciences-$101.87M-$1.41N/AN/AN/AN/A-43.08%-37.59%5/9/2024 (Estimated)MLNDMillendo Therapeutics-$36.41MN/A0.00∞N/AN/A-91.03%-72.44%N/ASVRASavara-$54.70M-$0.33N/AN/AN/AN/A-46.27%-35.94%5/20/2024 (Estimated)Latest KZR, SVRA, MLND, and ITRM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/28/2024Q4 2023ITRMIterum Therapeutics-$1.02-$0.94+$0.08-$0.94N/AN/A3/14/2024Q4 2023KZRKezar Life Sciences-$0.39-$0.35+$0.04-$0.26N/AN/A3/7/2024Q4 2023SVRASavara-$0.11-$0.09+$0.02-$0.09N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthITRMIterum TherapeuticsN/AN/AN/AN/AN/AKZRKezar Life SciencesN/AN/AN/AN/AN/AMLNDMillendo TherapeuticsN/AN/AN/AN/AN/ASVRASavaraN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioITRMIterum Therapeutics3.631.891.89KZRKezar Life Sciences0.0511.6611.66MLNDMillendo TherapeuticsN/A6.396.39SVRASavara0.1915.6615.66OwnershipInstitutional OwnershipCompanyInstitutional OwnershipITRMIterum Therapeutics9.21%KZRKezar Life Sciences67.90%MLNDMillendo TherapeuticsN/ASVRASavara87.93%Insider OwnershipCompanyInsider OwnershipITRMIterum Therapeutics5.40%KZRKezar Life Sciences7.90%MLNDMillendo TherapeuticsN/ASVRASavara4.58%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableITRMIterum Therapeutics1416.43 million15.54 millionNot OptionableKZRKezar Life Sciences5872.80 million67.05 millionNot OptionableMLNDMillendo Therapeutics1219.04 millionN/ANot OptionableSVRASavaraN/A138.15 million131.82 millionOptionableKZR, SVRA, MLND, and ITRM HeadlinesSourceHeadlineJMP Securities Reiterates "Market Outperform" Rating for Savara (NASDAQ:SVRA)americanbankingnews.com - April 20 at 1:54 AMFYBR, BCRX and SABR are among after hour moversseekingalpha.com - April 20 at 1:53 AMSavara's (SVRA) Market Outperform Rating Reiterated at JMP Securitiesmarketbeat.com - April 18 at 2:21 PMSavara (NASDAQ:SVRA) Trading Down 3.9%marketbeat.com - April 17 at 12:20 PMSavara (NASDAQ:SVRA) Sees Large Volume Increasemarketbeat.com - April 15 at 1:54 PMVanguard Group Inc. Buys 789,249 Shares of Savara Inc (NASDAQ:SVRA)marketbeat.com - April 14 at 4:16 AMSavara Calls Out Haters!ghettoradio.co.ke - April 13 at 12:23 PMSavara (NASDAQ:SVRA) Shares Up 3.6%marketbeat.com - April 11 at 1:47 PMOptimistic Buy Rating for Savara Based on Molgramostim’s Market Potential and Study Outcomesmarkets.businessinsider.com - April 11 at 8:38 AMSavara (NASDAQ:SVRA) Trading Up 2.6%marketbeat.com - April 4 at 12:45 AMDetails of Savara’s Upcoming Projectsghettoradio.co.ke - March 27 at 5:19 AMSavara Announces New Employment Inducement Grantbusinesswire.com - March 22 at 4:05 PMSavara: Why Sauti Sol had to take a break from each othermpasho.co.ke - March 19 at 4:25 AMSavara Inc. Reports Increased Expenses, Anticipates Positive Data from IMPALA-2 Trialmsn.com - March 13 at 1:33 PMFDA lifts partial hold on Nurix Phase 1 study for NX-2127msn.com - March 11 at 6:57 PMBuy Rating Affirmed: Anticipating IMPALA-2 Trial Success and aPAP Treatment Breakthrough with Molgramostimmarkets.businessinsider.com - March 11 at 1:57 PMSVRA Jul 2024 7.500 callfinance.yahoo.com - March 10 at 9:20 AMOptimistic Buy Rating for Savara on Molgramostim’s Market Potential and Strong Financialsmarkets.businessinsider.com - March 8 at 9:43 AMSVRA Stock Earnings: Savara Beats EPS for Q4 2023msn.com - March 7 at 11:08 PMSavara Reports Fourth Quarter/Year-End 2023 Financial Results and Provides Business Updatefinance.yahoo.com - March 7 at 6:08 PMBest penny stocks of March 2024usatoday.com - March 6 at 4:44 PMSavara to Present at the Barclays 26th Annual Global Healthcare Conferencefinance.yahoo.com - March 6 at 4:44 PMBensoul, Nviri, Savara, Father Moh, Jovial, Ndovu Kuu, and Mandy team up for new hit song 'Tujengane'mpasho.co.ke - March 2 at 9:23 AMPiper Sandler Keeps Their Buy Rating on Savara (SVRA)markets.businessinsider.com - March 1 at 2:54 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsIterum TherapeuticsNASDAQ:ITRMIterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.Kezar Life SciencesNASDAQ:KZRKezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.Millendo TherapeuticsNASDAQ:MLNDAs of June 25, 2021, Millendo Therapeutics, Inc. was acquired by Tempest Therapeutics Inc., in a reverse merger transaction. Millendo Therapeutics, Inc. operates as a biopharmaceutical company. The company is headquartered in Ann Arbor, Michigan.SavaraNASDAQ:SVRASavara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
